- Conditions
- Kidney Stones
- Interventions
- Empagliflozin (Jardiance®)
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Patients
- Interventions
- Empagliflozin, Dorzagliatin
- Drug
- Lead sponsor
- Hua Medicine Limited
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic, Non-diabetic, Kidney Dysfunction, Kidney Failure, Hemodialysis
- Interventions
- Empagliflozin, Placebo
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic Kidney Disease
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Palo Alto, California • Sacramento, California + 22 more
- Conditions
- Type 2 Diabetes (T2DM)
- Interventions
- SGLT-2 inhibitor, GLP1-RA
- Drug
- Lead sponsor
- MaryAnn Banerji
- Other
- Eligibility
- 24 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
- Interventions
- Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device, Placebo (Insulin Diluent), Placebo (Capsules)
- Drug · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina